NCT02620618View on ClinicalTrials.gov

Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Behçet's DiseaseUveitis
Interventions
DRUG

Intravitreal Infliximab

ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease

All Listed Sponsors
lead

Cairo University

OTHER

NCT02620618 - Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study | Biotech Hunter | Biotech Hunter